Karyopharm Q1 total revenue $33.1M, net loss $0.32/share; extends debt maturities to 2028/2029

Karyopharm Therapeutics Inc.

2024-Q1 EPS reported -$0.32 revenue$33,126,000

Q1 2024 total revenue $33.1M (vs $38.7M Q1 2023); U.S. XPOVIO net product revenue $26.0M (vs $28.3M Q1 2023).
Net loss $37.4M ($0.32 per share) vs $34.1M ($0.30 per share) in Q1 2023; R&D expenses $35.4M, SG&A $29.5M.
Reaffirms FY2024 guidance: total revenue $140-160M; XPOVIO net product revenue $100-120M; R&D+SG&A $260-280M.
Completed refinancing: extended majority of debt maturities to 2028/2029 and amended HCRx royalty, reducing royalty rate from 12.5% to 7.0%.
Cash, equivalents, restricted cash and investments $149.3M as of March 31, 2024; cash runway expected into end of 2025.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Karyopharm Therapeutics Inc. reported the quarter ended March 31, 2024 results: revenue $33.1 million. Guidance reaffirmed.

Period: the quarter ended March 31, 2024
Revenue: $33.1 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

Readouts and Potential Approvals from the Company’s Three Phase 3 Trials, Strengthening the Company for its Next Stage of Growth – – Achieves First Quarter 2024 Total Revenue of $33.1 Million and U.S. XPOVIO ® (selinexor) Net Product Revenue of $26.0 Million – – Reaffirms Full Year 2024 Total Revenue Guidance of $140.0 Million to $160.0 Million, Including U.S. XPOVIO

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Karyopharm Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-133784

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.